CoChat
Cited by 168

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

Open access
Scheen, André J., Charpentier, Guillaume, Östgren, Carl Johan, Hellqvist, Åsa, Gause‐Nilsson, Ingrid · 2010 · Diabetes/Metabolism Research and Reviews

Abstract

Background: Dipeptidyl peptidase‐4 inhibitors improve glycaemic control in patients with type 2 diabetes mellitus when used as monotherapy or in combination with other anti‐diabetic drugs (metformin, sulphonylurea, or thiazolidinedione). This 18‐week, phase 3b, multicentre, double‐blind, noninferiority trial compared the efficacy and safety of two dipeptidyl peptidase‐4 inhibitors, saxagliptin and sitagliptin, in patients whose glycaemia was inadequately controlled with metformin. Methods: Adult type 2 diabetes mellitus patients (N = 801) with glycated haemoglobin (HbA 1c) 6.5–10% on stable metformin doses (1500–3000 mg/day) were randomized 1 : 1 to add‐on 5 mg saxagliptin or 100 mg sitagliptin once daily for 18 weeks. The primary efficacy analysis was a comparison of the change from baseline HbA 1c at week 18 in per‐protocol patients. Noninferiority was concluded if the upper limit of the two‐sided 95% confidence interval of the HbA 1c difference between treatments was < 0.3%. Results: The adjusted mean changes in HbA 1c following the addition of saxagliptin or sitagliptin to stable metformin therapy were − 0.52 and − 0.62%, respectively. The between‐group difference was 0.09% (95% confidence interval, − 0.01 to 0.20%), demonstrating noninferiority. Both treatments were generally well tolerated; incidence and types of adverse events were comparable between groups. Hypoglycaemic events, mostly mild, were reported in approximately 3% of patients in each treatment group. Body weight declined by a mean of 0.4 kg in both groups. Conclusions: Saxagliptin added to metformin therapy was effective in improving glycaemic control in patients with type 2 diabetes mellitus inadequately controlled by metformin alone; saxagliptin plus metformin was noninferior to sitagliptin plus metformin, and was generally well tolerated. Copyright © 2010 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.1114

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Scheen, A. J., Charpentier, G., Östgren, C. J., Hellqvist, Å., & Gause‐Nilsson, I.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2010-09-07
Volume
26
Issue
7
Pages
540-549
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2114927834
Cited by
168
References
5
FWCI
18.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.